FHFreya Van Houtte

Freya Van Houtte

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Freya Van Houtte has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Virus–Host Protein Interaction Network of the Hepatitis E Virus ORF2-4 by Mammalian Two-Hybrid Assays

    by Laura Corneillie, Irma Lemmens, Karin Weening, Amse De Meyer, Freya Van Houtte, Jan Tavernier, Philip Meuleman

    Throughout their life cycle, viruses interact with cellular host factors, thereby influencing propagation, host range, cell tropism and pathogenesis. The hepatitis E virus (HEV) is an underestimated RNA virus in which knowledge of the virus–host interaction network to date is limited. Here, two related high-throughput mammalian two-hybrid approaches (MAPPIT and KISS) were used to screen for HEV-interacting host proteins. Promising hits were examined on protein function, involved pathway(s), and their relation to other viruses. We identified 37 ORF2 hits, 187 for ORF3 and 91 for ORF4. Several hits had functions in the life cycle of distinct viruses. We focused on SHARPIN and RNF5 as candidate hits for ORF3, as they are involved in the RLR-MAVS pathway and interferon (IFN) induction during viral infections. Knocking out (KO) SHARPIN and RNF5 resulted in a different IFN response upon ORF3 transfection, compared to wild-type cells. Moreover, infection was increased in SHARPIN KO cells and decreased in RNF5 KO cells. In conclusion, MAPPIT and KISS are valuable tools to study virus–host interactions, providing insights into the poorly understood HEV life cycle. We further provide evidence for two identified hits as new host factors in the HEV life cycle.


  • Development and characterization of a human monoclonal antibody targeting the N-terminal region of hepatitis C virus envelope glycoprotein E1

    by Ahmed Atef Mesalam, Isabelle Desombere, Ali Farhoudi, Freya Van Houtte, Lieven Verhoye, Jonathan Ball, Jean Dubuisson, Steven K.H. Foung, Arvind H. Patel, Mats A.A. Persson, et al.


  • Open Access

    A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo

    by Isabelle Desombere, Ahmed Atef Mesalam, Richard A. Urbanowicz, Freya Van Houtte, Lieven Verhoye, Zhen-Yong Keck, Ali Farhoudi, Koen Vercauteren, Karin E. Weening, Thomas F. Baumert, et al.


  • Monoclonal anti‐envelope antibody AP33 protects humanized mice against a patient‐derived hepatitis C virus challenge

    by Isabelle Desombere, Samira Fafi‐Kremer, Freya Van Houtte, Patrick Pessaux, Ali Farhoudi, Laura Heydmann, Lieven Verhoye, Sarah Cole, Jane A. McKeating, Geert Leroux‐Roels, et al.

    Gression. Currently available direct‐acting antiviral therapies have reduced efficacy in patients with ESLD and prophylactic strategies to prevent HCV recurrence are still highly needed. In this study, we compared the ability of two broadly reactive monoclonal antibodies (mAbs), designated 3/11 and AP33, recognizing a distinct, but overlapping, epitope in the viral E2 glycoprotein to protect humanized mice from a patient‐derived HCV challenge. Their neutralizing activity was assessed using the HCV pseudoparticles and cell‐culture–derived HCV systems expressing multiple patient‐derived envelopes and a human‐liver chimeric mouse model. HCV RNA was readily detected in all control mice challenged with a patient‐derived HCV genotype 1b isolate, whereas 3 of 4 AP33‐treated mice were completely protected. In contrast, only one of four 3/11‐treated mice remained HCV‐RNA negative throughout the observation period, whereas the other 3 had a viral load that was indistinguishable from that in the control group. The increased in vivo efficacy of AP33 was in line with its higher affinity and neutralizing capacity observed in vitro. Conclusions: Although mAbs AP33 and 3/11 target the same region in E2, only mAb AP33 can efficiently protect from challenge with a heterologous HCV population in vivo. Given that mAb AP33 efficiently neutralizes viral variants that escaped the humoral immune response and reinfected the liver graft of transplant patients, it may be a valuable candidate to prevent HCV recurrence. In addition, our data are valuable for the design of a prophylactic vaccine. (Hepatology 2016;63:1120–1134)...